IPP Bureau
Dipharma receives regulatory authorization for the new line at Its cGMP pilot plant
By IPP Bureau - October 09, 2022
The company increases its efficiency and is able to face the growing demand for its services.
LISSUN announces 2nd edition of its campaign -'#LISSUNToYourMind'
By IPP Bureau - October 09, 2022
Campaign to celebrate World Mental Health Day theme "Mental Health in an Unequal World"
Pfizer acquires Global Blood Therapeutics
By IPP Bureau - October 09, 2022
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
Pfizer announces positive topline results from Phase 3 TALAPRO-2 trial
By IPP Bureau - October 09, 2022
Study achieves primary endpoint of radiographic progression-free survival
BioMarin simplifies organizational structure to increase efficiency
By IPP Bureau - October 09, 2022
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
ICON selected by BARDA to conduct anthrax vaccine clinical trial
By IPP Bureau - October 09, 2022
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults
By IPP Bureau - October 07, 2022
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Presss note on WHO Medical product alert regarding Maiden Pharmaceuticals
By IPP Bureau - October 07, 2022
DSCO has requested WHO to share at the earliest with CDSCO the report on establishment of causal relation to death with the medical products in question etc.
Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets
By IPP Bureau - October 07, 2022
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
L&T Construction bags order to construct manufacturing facility in Haryana
By IPP Bureau - October 07, 2022
This win is on the back of a prestigious order from Reliance Life Sciences
Lupin appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer
By IPP Bureau - October 07, 2022
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Atul Healthcare to acquire stake in VIMS
By IPP Bureau - October 05, 2022
The agreement provides for acquisition of 13,50,000 equity shares of Rs. 100 each constituting 50% of the total equity share capital
Granules India inaugurated water tank at Bonthapally village
By IPP Bureau - October 05, 2022
The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.
NATCO launches Chlorantraniliprole combination agro products in India
By IPP Bureau - October 05, 2022
Both products are broad-spectrum, foliar insecticides used across wide range of crops
Lupin receives approval from USFDA for Darunavir Tablets
By IPP Bureau - October 05, 2022
The product will be manufactured at Lupin's facility in Nagpur, India.
